Form 4: Craig Wheeler Reports Acquisition of Apellis Pharmaceuticals Stock and Stock Options

Director Craig Wheeler reports the acquisition of 16,483 shares of common stock and 28,195 stock options in Apellis Pharmaceuticals on April 17, 2025.

Summary

• Craig Wheeler, a director of Apellis Pharmaceuticals, reported acquiring 16,483 shares of common stock on April 17, 2025.
• These shares were acquired at a price of $0.
• Wheeler also acquired 28,195 stock options with an exercise price of $18.20 on the same date.
• The stock options vest 1/3rd per year over a three-year period, contingent upon continued service.
• The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election.
• Following these transactions, Wheeler directly owns 16,483 shares of Apellis Pharmaceuticals common stock and 28,195 stock options.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard regulatory filing detailing stock and option acquisitions. The director's actions could be seen as a positive signal, but it's not overtly promotional.

Positives

• The acquisition of shares and stock options by a director could be interpreted as a sign of confidence in the company's future prospects.

Future Outlook

The vesting schedule of the stock options and restricted stock units is contingent upon continued service, suggesting an ongoing commitment from the director.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. They are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The acquisition of shares by a director may positively influence shareholder sentiment.

Key Dates

Keywords

Apellis Pharmaceuticals, Craig Wheeler, stock options, Form 4, director, stock acquisition, beneficial ownership